Press release
Unveiling the Future of Abdominal Aortic Aneurysm Pipeline: Cutting-Edge Research and Breakthroughs | Companies- Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, and others
Glaucoma Pipeline
The Glaucoma pipeline analysis report for Glaucoma emerging drugs offers a comprehensive and holistic perspective of the therapeutic landscape. It encompasses the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Glaucoma pipeline covers multiple facets including business opportunities, challenges, potential partnerships, formidable competitors, and growth strategies. Each drug is described in detail, including its mechanism of action, Glaucoma clinical trial studies conducted for Glaucoma, any obtained Glaucoma NDA approvals, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other pertinent information.
To explore more information on the latest breakthroughs in the Glaucoma Pipeline treatment landscape of the report, click here @ Glaucoma Pipeline Outlook- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Glaucoma Pipeline Report
• DelveInsight's Glaucoma Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
• The leading Glaucoma Companies are working in the market include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, Bayer, Regeneron Pharmaceuticals, Allergan, AqueSys Inc, Novartis Pharmaceuticals, AbbVie, Alcon Research, and others
• Promising Glaucoma Pipeline Therapies in the various stages of development include GmbH NCX 470, DE-126, POLAT 001, BTQ-1902, ST266, Brinzolamide/Timolol Maleate Fixed Combination (AZARGA), Travoprost 0.004% ophthalmic solution, Aflibercept (Eylea, BAY 86-5321), and others
• NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog that is currently being developed by Nicox Ophthalmics. NCX-470 may assist glaucoma patients by a mechanism other than IOP lowering, notably by enhancing ocular perfusion. IOP reduction is the most common treatment for glaucoma, and preliminary studies suggest that if approved, NCX-470's dual mechanistic approach (nitric oxide donation and prostaglandin F2 activity) could make it the most effective single-agent glaucoma medicine in terms of IOP-lowering efficacy. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.
• DE-126 (ONO-9054) is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, ONO-9054 is expected to give a new therapeutic options for the treatment of glaucoma. It is likely to show a superior IOP lowering effect compared to FP receptor agonists. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.
Glaucoma Overview
Glaucoma is a group of eye conditions that damage the optic nerve. The optic nerve sends visual information from eye to the brain and is vital for good vision. Damage to the optic nerve is often related to high pressure in your eye. But glaucoma can happen even with normal eye pressure. Glaucoma can occur at any age but is more common in older adults. It is one of the leading causes of blindness for people over the age of 60.
For further information, refer to the detailed Glaucoma Unmet Needs, Glaucoma Market Drivers, and Glaucoma Market Barriers, click here for Glaucoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Glaucoma Emerging Drugs Profile
• GmbH NCX 470: Nicox Ophthalmics
• DE-126: Santen Pharmaceuticals
• POLAT 001: Peregrine Ophthalmic
• BTQ-1902: Betaliq, Inc.
• ST266: Noveome Biotherapeutics
Glaucoma Pipeline Therapeutics Assessment
There are approx. 50+ Glaucoma companies which are developing the therapies for Glaucoma Disease. The Glaucoma companies which have their Glaucoma Disease drug candidates in the most advanced stage, i.e. phase III include, Nicox Ophthalmics.
Request a sample and discover the recent advances in Glaucoma Ongoing Clinical Trial Analysis and Medications, click here @ Glaucoma Treatment Landscape- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Glaucoma Pipeline Segmentation
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Glaucoma Therapeutics Market include-
Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, Bayer, Regeneron Pharmaceuticals, Allergan, AqueSys Inc, Novartis Pharmaceuticals, AbbVie, Alcon Research, and others.
Dive deep into rich insights for drugs for Glaucoma Pipeline, click here @ Glaucoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Glaucoma Pipeline Report
• Coverage- Global
• Glaucoma Companies- Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, Bayer, Regeneron Pharmaceuticals, Allergan, AqueSys Inc, Novartis Pharmaceuticals, AbbVie, Alcon Research, and others.
• Glaucoma Pipeline Therapies- GmbH NCX 470, DE-126, POLAT 001, BTQ-1902, ST266, Brinzolamide/Timolol Maleate Fixed Combination (AZARGA), Travoprost 0.004% ophthalmic solution, Aflibercept (Eylea, BAY 86-5321), and others
• Glaucoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Glaucoma Mergers and acquisitions, Glaucoma Licensing Activities @ Glaucoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Glaucoma Executive Summary
3. Glaucoma Disease: Overview
4. Glaucoma Pipeline Therapeutics
5. Glaucoma Therapeutic Assessment
6. Glaucoma Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. NCX 470: Nicox Ophthalmics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. POLAT 001: Peregrine Ophthalmic
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ST266: Noveome Biotherapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. RTC-1119: Ripple Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Glaucoma Disease Key Companies
21. Glaucoma Disease Key Products
22. Glaucoma Disease- Unmet Needs
23. Glaucoma Disease- Market Drivers and Barriers
24. Glaucoma Disease- Future Perspectives and Conclusion
25. Glaucoma Disease Analyst Views
26. Glaucoma Disease Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Unveiling the Future of Abdominal Aortic Aneurysm Pipeline: Cutting-Edge Research and Breakthroughs | Companies- Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, and others here
News-ID: 3082788 • Views: …
More Releases from DelveInsight Business Research
Neurotrophic Keratitis Market Report 2032: Epidemiology Data, Pipeline Therapies …
DelveInsight's "Neurotrophic Keratitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neurotrophic Keratitis, historical and forecasted epidemiology as well as the Neurotrophic Keratitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurotrophic Keratitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratitis Market Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key…
Keratoconus Market to Exhibit Rapid Growth Rate During the Forecast Period (2023 …
DelveInsight's "Keratoconus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Keratoconus, historical and forecasted epidemiology as well as the Keratoconus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Keratoconus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Keratoconus Market Forecast
https://www.delveinsight.com/sample-request/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Keratoconus…
Cancer Cachexia Market to Observe Impressive Growth During the Forecast Period ( …
DelveInsight's "Cancer Cachexia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cancer Cachexia, historical and forecasted epidemiology as well as the Cancer Cachexia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Cancer Cachexia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Cachexia Market Forecast
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Chemotherapy Induced Neutropenia Market is Expected to Expand at a Healthy Growt …
DelveInsight's "Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia…
More Releases for Glaucoma
Micro-Invasive Glaucoma Implants Micro-Invasive Glaucoma Implants
Global Micro-Invasive Glaucoma Implants Market Definition: Micro-invasive glaucoma implants is performed for the treatment of the open- angle glaucoma and is done through an ab- interno approach. It is very safe and provides faster recovery as compared to the traditional methods. They usually lower the intraocular by increasing the flow or reducing the production of the aqueous humor. Increasing cases of the glaucoma worldwide is the major factor fueling the…
Glaucoma – Epidemiology Insights (2016-2028)
Glaucoma can be described as a group of diseases characterized by cupping of the optic nerve head and visual-field damage. These diseases differ from each other in terms of their causes, risk factors, demographics, symptoms, duration, treatment, and prognosis.
Download the sample report @ https://www.pharmaproff.com/request-sample/1159
The common identifiable features for all forms of glaucoma are loss of retinal ganglion cells, thinning of the retinal nerve fiber layer, and cupping of the…
Market Spotlight: Glaucoma
Boston, MA
ReportsWorldwide has announced the addition of a new report title Market Spotlight: Glaucoma to its growing collection of premium market research reports.
Glaucoma is not just one eye disease, but a group of eye conditions resulting in optic nerve damage, which may cause loss of vision and blindness. In glaucoma, damage to the optic nerve is usually caused by elevated intraocular pressure (IOP). IOP rises when passages that allow fluid…
North America Glaucoma Therapeutics Market grows with growing awareness regardin …
Glaucoma Therapeutics Market: Scope and Methodology
The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study…
Glaucoma Treatment Market : Rising Geriatric Population And Healthcare Expenditu …
Glaucoma is a chronic, degenerative, permanent disorder whose rate increases essentially with age rather than causing immediate blindness. According to a survey of WHO, Glaucoma is the second most common cause of blindness affecting the population worldwide after cataract (47.9%). In general, Glaucoma occurs as after effects of increased intraocular pressure (IOP) brought about by an abnormality or malfunctioning of the eye drainage system. The normal IOP is in…
Glaucoma Surgery Devices Market 2016: Glaucoma Systems, Glaucoma Laser Devices
Latest industry research report on Glaucoma surgery devices are used in the glaucoma treating procedure. These procedures include both surgical and laser therapies performed on a patient. The cases of blindness due to glaucoma is on rise across the several countries. Furthermore, the demand for both technologically as well as advanced surgical equipment has resulted in the popularity of glaucoma surgery devices industry, worldwide.
Sudden increase in the aging population and…
